7 terminated. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
Follow Breast Neoplasm: new trials by email Literature Review of Breast Neoplasm trials Research Report on Breast Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Abemaciclib, Fulvestrant - Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Terminated | University of California, Irvine | 1 | 2020-07-23 | 2023-06-06 |
| Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC Decitabine, Carboplatin - Breast Neoplasm | Phase 2 | Terminated | Shanghai Jiao Tong University School of Medicine | 12 | 2017-11-15 | 2022-04-06 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Trilaciclib, Gemcitabine, Carboplatin - Triple-Negative Breast Neoplasms, Breast Neoplasm | Phase 2 | Terminated | G1 Therapeutics, Inc. | 102 | 2017-02-02 | 2022-03-23 |
| [18F]FES PET/CT in Endocrine Refractory Breast Cancer [18F]FES - Estrogen Receptor Positive Breast Cancer, Breast Neoplasm | Phase 2 | Terminated | University of Pennsylvania | 6 | 2015-10-15 | 2026-06-11 |
| Study of AFP464 +/- Faslodex in ER + Breast Cancer AFP464, AFP464 + Faslodex - Breast Neoplasm | Phase 2 | Terminated | Tigris Pharmaceuticals | 7 | 2011-05-01 | 2012-01-09 |
| A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer 18F-FAZA PET scan, FluGlucoScan Injection (18F-FDB) PET scan - Breast Neoplasm | Phase 2 | Terminated | AHS Cancer Control Alberta | 23 | 2008-11-28 | 2019-08-22 |
| Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) temozolomide - Breast Neoplasm, Brain Neoplasm | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 6 | 2008-10-02 | 2017-06-14 |
Breast Neoplasms (7) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Brain Neoplasms (1) · Neoplasms, Second Primary (1)
Breast Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Carboplatin (2) · Fulvestrant (2) · 16-fluoroestradiol (1) · Decitabine (1) · Gemcitabine (1) · Magnetic Resonance Spectroscopy (1) · Temozolomide (1) · abemaciclib (1) · aminoflavone (1) · trilaciclib (1)
AHS Cancer Control Alberta (1) · G1 Therapeutics, Inc. (1) · Merck Sharp & Dohme LLC (1) · Shanghai Jiao Tong University School of Medicine (1) · Tigris Pharmaceuticals (1) · University of California, Irvine (1) · University of Pennsylvania (1)
United States (4) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Croatia (1) · North Macedonia (1) · Serbia (1) · Slovakia (1) · Slovenia (1)
David Mankoff, MD. PhD (1) · Emmanuel W Hudson, MD (1) · Joanne L. Blume, M.D. (1) · Kunwei Shen, MD (1) · Min Lu, PHD (1) · Ritesh Parajuli, MD (1)
2016 (1)